During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with non–small cell lung cancer.
Targeted Therapy Options for Patients With KRAS-Mutated NSCLC
During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the KRAS-mutated non–small cell lung cancer population.
During a Targeted Oncology™ Case-Based Roundtable™ event, Anne S. Tsao discussed with participants
Shirish M. Gadgeel, MD, MBBS, discusses the results of the KRYSTAL-1 trial trial of adagrasib in patients with KRAS-positive non–small cell lung cancer.